China Pharmaceutical Sector Report 2017 4th QuarterAn EMIS Insights Industry Report
EMIS is a Euromoney Institutional Investor plc company Date: February 2018
Available in: English
In the third quarter of 2017, all subsectors of China’s pharmaceutical manufacturing sector, except the ready-prepared traditional Chinese medicines (TCMs), marked y/y growth in their revenues. The sizeable decline of 26.9% y/y in the TCM subsector’s revenue, however, had a negative impact on the whole sector’s revenue, which totalled RMB 726.2bn, down by 1.8% y/y. The sector’s total profit rose 15.9% to RMB 87.1bn, driven by the gradual implementation of the “two invoices” system. As a result of the ongoing environmental inspection campaign in Q3 2017 the production volume of pharmaceutical and medical products dropped by 1.5% y/y to 801,000 tonnes. The closure of a number of heavy-polluting producers of active pharmaceutical ingredients (APIs) caused a significant increase in API product prices. In Q3 2017 both the imports and the exports of pharmaceutical products marked y/y increases in value and volume terms. In this period the imports of pharmaceutical and medical products rose by 9.2% y/y to USD 6.5bn, while the exports increased by 9.1% y/y to USD 3.7bn. The number of pharmaceutical enterprises in China rose to 8,710 at the end of September 2017. Of these, 1,075 were loss making enterprises, compared to 1,119 at end-June and 1,373 at end-March 2017. The profitability of pharmaceutical manufacturers improved significantly after the implementation of the “two invoices” systems, which simplified drug supply chain and reduced distribution expenses.
What this report allows you to do:
- Understand the key elements at play in the pharmaceutical sector in China
- Access forecasts for growth in the sector
- View key data on production and sales for the sector in China
- Crystallise the forces both driving and restraining this sector in China
- Build a complete perspective on sector trade, investment and employment
- Understand the competitive landscape and who the major players are
- View M&A activity and major deals
- Gain an understanding of the regulatory environment for the sector in China
- Build a clear picture of trends and issues for sub-sectors (western medicine, traditional Chinese medicine).
See below for a complete table of report contents: